Literature DB >> 28691363

Glaucoma Australia educational impact study: a randomized short-term clinical trial evaluating the association between glaucoma education and patient knowledge, anxiety and treatment satisfaction.

Simon E Skalicky1,2,3, Guy D'Mellow4,5, Philip House6, Eva Fenwick3,7,8.   

Abstract

IMPORTANCE: Targeted education may impact glaucoma patients' clinical experience.
BACKGROUND: The aim of this study was to measure the impact of patient-centred glaucoma-related education on knowledge, anxiety and treatment satisfaction.
DESIGN: This was a multicentre Australia-wide randomized clinical trial. PARTICIPANTS: One hundred one newly diagnosed glaucoma patients were randomized 1:1 to intervention or control groups.
METHODS: Those randomized to the Glaucoma Australia educational intervention received telephone-based counselling about glaucoma followed by mail-out information, in addition to usual care and information from their treating ophthalmologist. The control group received only usual care and information from their treating ophthalmologist. Surveys were administered at baseline and 4 weeks following intervention. MAIN OUTCOME MEASURES: The Auckland Glaucoma Knowledge Questionnaire measured glaucoma-related knowledge. The Hospital Anxiety and Depression Scale and Eye-Drop Satisfaction Questionnaire measured anxiety and patient treatment satisfaction, respectively.
RESULTS: Mean age was 64.7 ± 11.1 years, and 52 (51.5%) were male. There was no noticeable increase in knowledge levels in the control group (mean difference: 0.04 logits, P = 0.7), compared with a 0.49-logit (P = 0.02) increase in knowledge levels in the intervention group. Between-group comparison showed a non-significant increase in knowledge (0.45 logits, P = 0.07) comparing intervention participants with controls. Intervention participants experienced a statistically significant decrease in anxiety compared to controls (-0.60 logits, P = 0.02). No between-group difference was found in Eye-Drop Satisfaction Questionnaire scores. CONCLUSIONS AND RELEVANCE: Patient-centred glaucoma-related education and support services may improve knowledge and can reduce anxiety for newly diagnosed glaucoma patients. All glaucoma patients should be adequately counselled about the nature of the disease and its management.
© 2017 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  education; glaucoma; quality of life

Mesh:

Year:  2017        PMID: 28691363     DOI: 10.1111/ceo.13016

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  5 in total

1.  Knowledge and awareness of glaucoma in Mexican patients with and without glaucoma diagnosis in an Ophthalmology Referral Center.

Authors:  Valeria Becerril-Ledezma; Daniela Alvarez-Ascencio; Clarisa Esther Del Hierro-Gutiérrez; Alejandra Hernandez-Oteyza; Jesús Jiménez-Román
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

Review 2.  Patient-centred care in ophthalmology: current practices, effectiveness and challenges.

Authors:  Shing Chuen Chow; Pun Yuet Lam; Bonnie Nga Kwan Choy
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-21       Impact factor: 3.535

3.  Patient satisfaction with care in an urban tertiary referral academic glaucoma clinic in the US.

Authors:  Kristen M Peterson; Carrie E Huisingh; Christopher Girkin; Cynthia Owsley; Lindsay A Rhodes
Journal:  Patient Prefer Adherence       Date:  2018-05-09       Impact factor: 2.711

4.  Lessons learned from the development and implementation of a patient-reported outcome and experience measure (POEM) in an Australian glaucoma practice.

Authors:  Alison Fraenkel; Graham A Lee; Stephen J Vincent; Roslyn A Vincent; Rupert R A Bourne; Peter Shah
Journal:  BMC Ophthalmol       Date:  2019-08-22       Impact factor: 2.209

5.  Medicine treatment of glaucoma in Australia 2012-2019: prevalence, incidence and persistence.

Authors:  Benjamin Daniels; Paul Healey; Claudia Bruno; Iain Kaan; Helga Zoega
Journal:  BMJ Open Ophthalmol       Date:  2021-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.